June 15, 2011 - Patent covers endoscopically implantable devices representing significant innovation in the treatment of metabolic diseases, including obesity and type 2 diabetes - EndoSphere Inc., a medical technology company that holds 23 U.S. and international issued and pending patents, announced that the U.S. Patent and Trademark Office has issued the company a patent covering the use of its endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes.U.S. Patent number 7,931,693 titled "Method and Apparatus for Reducing Obesity" describes a noninvasive device that uses the body's natural physiology to regulate appetite and satiety among other potential uses.
"This strong initial patent position, in combination with significant clinical interest, makes EndoSphere an attractive partner in the rapidly growing fields of interventional gastroenterology and obesity treatments... EndoSphere's Press Release -
